Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 2 3Phase 3 2

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hyperuricemia 3Tumor Lysis Syndrome 2Recurrence 1Neoplasms 1Lymphoma 1Leukemia 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × rasburicase × Clear all
NCT00302653 2009-09-25

Rasburicase in Tumor Lysis Syndrome

Sanofi

Phase 4 Completed
33 enrolled

Hyperuricemia

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

NCT00651911 2008-04-03

Fasturtec TLS Treatment / Prophylysis

Sanofi

Phase 4 Completed
45 enrolled

Tumor Lysis Syndrome

NCT00563771 2008-01-28

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Sanofi

Phase 4 Completed
38 enrolled

Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡